BioWorld MedTech

Sep. 1, 2017

Abbott seeks indication for Amplatzer to treat heart defects in pre-term infants

Abbott Laboratories has initiated a U.S. pivotal clinical study evaluating a modified version of its Amplatzer device designed to correct a common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year. Read More

Researchers behind newly funded Neuros get $2M from NIH for nerve-block studies

Hologic's Brevera biopsy system hits U.S. market

CDSC inks voluntary guidelines for medium-risk CDS systems

New factor helps old iPSCs

Holiday notice

Product briefs

Other news to note

Regulatory front

BioWorld MedTech's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...